Ublituximab clinical trials
Also written TG-1101, BRIUMVI and TG-20.
How each study uses ublituximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ublituximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Dec 2022 · BRIUMVI · BLA 761238 (FDA, Drugs@FDA)
- European Union
- 31 May 2023 · Briumvi · EMEA/H/C/005914 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 4 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 3 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 14
TG Therapeutics, Inc. (22) · City of Hope Medical Center (2) · Johns Hopkins University (2) · Jennifer R. Brown, MD, PhD (1) · University of Colorado, Denver (1) · Laboratoire français de Fractionnement et de Biotechnologies (1) · Jonathan Santoro (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
Umbralisib (12) · Acalabrutinib (1) · Fingolimod (1) · Cosibelimab (1) · Tazemetostat (1) · Lenalidomide (1)
Related medicines
As reviewed, each with the page that says it.
- One of Immunomodulating Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test ublituximab, phase 3 first.
- Jan 2027Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 3 · TG Therapeutics, Inc.
- Jul 2027A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)Phase 2 · TG Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses ublituximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 37
- Ublituximab in Autoantibody Positive Immune Mediated Necrotizing MyopathyRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07103746Written as Ublituximab
- Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaRecruitingPhase 2TG Therapeutics, Inc.NCT07680946Written as Ublituximab
- A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)RecruitingPhase 2TG Therapeutics, Inc.NCT07503873Written as Ublituximab
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)RecruitingPhase 2TG Therapeutics, Inc.NCT07673744Written as Ublituximab
- Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisRecruitingPhase 2/3TG Therapeutics, Inc.NCT07220252Written as Ublituximab
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabRecruitingPhase 3TG Therapeutics, Inc.NCT05877963Written as Ublituximab
- An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression DisorderNot yet recruitingPhase 2Jonathan SantoroNCT07812181Written as Ublituximab
- Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple SclerosisRecruitingNot applicableUniversity of Maryland, BaltimoreNCT06864936Written as Ublituximab
- Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisRecruitingPhase 4Johns Hopkins UniversityNCT07389590Written as Ublituximab
- Ublituximab (Briumvi) for Early Forms of Relapsing Multiple SclerosisRecruitingPhase 4Northwestern UniversityNCT07225361Written as Ublituximab
- Effects of Ublituximab on Motor Functions in Multiple SclerosisRecruitingEarly Phase 1Georgia State UniversityNCT06629428Written as Ublituximab
- An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisActive, not recruitingPhase 3TG Therapeutics, Inc.NCT04130997Written as Ublituximab
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3TG Therapeutics, Inc.NCT07211633Written as Ublituximab
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingPhase 2City of Hope Medical CenterNCT04783415Written as Ublituximab
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingPhase 2Jennifer R. Brown, MD, PhDNCT04624633Written as Ublituximab
- Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedPhase 3TG Therapeutics, Inc.NCT02612311Written as Ublituximab
- Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)TerminatedPhase 2/3TG Therapeutics, Inc.NCT03801525Written as Ublituximab
- Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone LymphomaCompletedPhase 2University of Colorado, DenverNCT04508647Written as Ublituximab
- Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)TerminatedPhase 1/2University of Alabama at BirminghamNCT04692155Written as Ublituximab
- Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedPhase 2TG Therapeutics, Inc.NCT03828448Written as Ublituximab
See all 37 studies that test ublituximab →
Given beside what is tested · 7 — ublituximab is usual care or a partner of the new treatment
- Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedPhase 1TG Therapeutics, Inc.NCT04806035Written as Ublituximab
- Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesTerminatedPhase 1TG Therapeutics, Inc.NCT03671590Written as Ublituximab
- Study of TG-1801 in Subjects With B-Cell LymphomaCompletedPhase 1TG Therapeutics, Inc.NCT03804996Written as Ublituximab
- Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedPhase 2TG Therapeutics, Inc.NCT04016805Written as Ublituximab
- Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's TransformationCompletedPhase 1TG Therapeutics, Inc.NCT02535286Written as ublituximab
- Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLTerminatedPhase 1/2TG Therapeutics, Inc.NCT03379051Written as Ublituximab
- Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedPhase 2/3TG Therapeutics, Inc.NCT02793583Written as Ublituximab
Codes
What other systems call ublituximab · ClinicalTrials.gg INT000673
- MeSH (NLM) C000619007ublituximabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) U59UGK3IPCUBLITUXIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7876570ublituximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91078UblituximabOne source FDA
- DrugBank DB11850One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619007 | ublituximab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | U59UGK3IPC | UBLITUXIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7876570 | ublituximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91078 | Ublituximab | One source FDA |
| DrugBank | DB11850 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.